Tyra Biosciences, Inc. TYRA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -39.8%-8.2pp | -31.6%-1.7pp | -29.9%-10.1pp | -19.8%— | |
| Return on assets | -37.1%-7.8pp | -29.3%-1.2pp | -28.1%-8.8pp | -19.3%-3.0pp | |
| Return on invested capital | -59.7%-8.9pp | -50.8%+47.9pp | -98.7%+1,083pp | -1,181.3%— | |
| Liquidity | |||||
| Current ratio | 14.7×-9.1× | 23.8×+10.0× | 13.8×-31.3× | 45.1×-39.0× | |
| Quick ratio | 14.7×-9.1× | 23.8×+10.0× | 13.8×-31.3× | 45.1×-39.0× | |
| Cash ratio | 4.3×-2.0× | 6.3×+2.5× | 3.8×-40.3× | 44.1×-39.5× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $4.35-27.5% | $6.00+25.4% | $4.78-22.3% | $6.16-71.9% | |
| Valuation | |||||
| Market capitalization | $1.4B+99.5% | $703.38M+18.2% | $595.08M+85.5% | $320.78M-45.1% | |
| Enterprise value | $1.33B+116% | $617.64M+13.6% | $543.57M+653% | $72.19M-74.5% | |
| Price / book | 5.4×+3.4× | 2×-0.9× | 2.9×+1.7× | 1.2×-0.7× | |
| Free cash flow yield | -6.8%+3.2pp | -10%-1.5pp | -8.6%+7.3pp | -15.9%-11.7pp | |
| Earnings yield | -8.5%+3.7pp | -12.3%-0.7pp | -11.6%+5.6pp | -17.2%-12.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tyra Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Tyra Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.